Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
| Autor: | Szilasiová J; Department of Neurology, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic/Department of Neurology, L. Pasteur University Hospital, Košice, Slovak Republic., Mikula P; Department of Social and Behavioural Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic., Rosenberger J; Department of Health Psychology and Methodology of Research, II. Internal Clinic, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic/Olomouc University Social Health Institute, Palacky University Olomouc, Olomouc, Czech Republic., Fedičová M; Department of Neurology, L. Pasteur University Hospital, Košice, Slovak Republic., Gdovinová Z; Department of Neurology, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic/Department of Neurology, L. Pasteur University Hospital, Košice, Slovak Republic., Urban P; Department of Medical and Clinical Biochemistry, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic., Frigová L; Pro Magnet, Košice, Slovak Republic. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2021 Nov; Vol. 27 (13), pp. 2023-2030. Date of Electronic Publication: 2021 Feb 26. |
| DOI: | 10.1177/1352458521998039 |
| Abstrakt: | Background: The research is focused on sensitive biomarkers in multiple sclerosis (MS). Objective: The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept NEDA (no evident disease activity), including brain volumetry, in a cohort of MS patients treated with disease-modifying treatment (DMT). Methods: Levels of pNfL (Single Molecule Array (SIMOA) technology) were examined in 95 RRMS (relapsing-remitting multiple sclerosis) patients and analyzed in relationship to NEDA-3 status and NEDA-BVL (brain volume loss; NEDA-3 extended by brain volumetry) during the last 12 months. The statistical model was developed using logistic regression analysis, including the independent variables: demographic, clinical, and magnetic resonance imaging (MRI) data. Dependent variables were NEDA-3 and NEDA-BVL status. Results: The mean age of the study participants ( n = 95, 62% females) was 37.85 years (standard deviation (SD) = 9.62) and the median disability score was 3.5 (2.5-4.1). Receiver operating characteristics (ROC) analysis showed that pNfL predicts NEDA-3 (the sensitivity and specificity of the model were 92% and 78%, respectively, p < 0.001) and NEDA-BVL status (the sensitivity and specificity were 80% and 65%, respectively, p < 0.001). Conclusion: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA-BVL status, including brain MRI-volumetry in patients with RRMS. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|